ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2113

Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

Dennis McGonagle1, Derek Haaland2, Philip Helliwell3, A. Marilise Marrache4, May Shawi5, Emmanouil Rampakakis6, Peter Nash7, Fedra Irazoque Palazuelos8 and Arthur Kavanaugh9, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2The Waterside Clinic, Oro Medonte, ON, Canada, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7School of Medicine, Griffith University, Sunshine Coast, Australia, 8Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico, 9University of California San Diego, La Jolla, CA

Meeting: ACR Convergence 2022

Keywords: American College of Rheumatology Criteria, Biologicals, clinical trial, Outcome measures, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster III: PsA

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria. Using data from the phase 3 DISCOVER-1 and DISCOVER-2 (D1/D2) studies in pts with active PsA, the purpose of this analysis was to describe the benefit of the IL-23p19 inhibitor, guselkumab (GUS), vs placebo (PBO) across key PsA domains, including those not comprising the core ACR measures, in pts not meeting ACR response criteria.

Methods: Pts enrolled in D1 and D2 were adults with active PsA despite standard therapies. D1 pts had ≥3 swollen and ≥3 tender joints (SJC; TJC) and CRP ≥0.3 mg/dL; D2 pts had SJC ≥5, TJC ≥5 TJC, and CRP ≥0.6 mg/dL. 31% of D1 pts received 1-2 prior tumor necrosis factor inhibitors (TNFi); D2 pts were biologic-naïve. Pts were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then Q8W; or PBO; PBO pts crossed over to GUS 100 mg Q4W at W24. In this post hoc analysis, patients not meeting ≥20% improvement in ACR response criteria (ACR20) at W24 were included. Changes from baseline (BL) over 24 W in continuous outcomes of interest (SJC; TJC; enthesitis/dactylitis scores; psoriasis area and severity index [PASI] score; Functional-Assessment of Chronic Illness Therapy [FACIT]-fatigue score; and SF-36 physical [PCS] & mental [MCS] component summary scores) were assessed with repeated measures mixed models adjusting for treatment group, baseline non-biologic DMARD use, and prior TNFi use. Descriptive statistics were produced for categorical outcomes at W24 (Figure 1) using non-responder imputation for missing data.

Results: Of the 1120 pooled D1/D2 pts, 538 did into achieve an ACR20 response at W24, including 137 (36.7%) GUS Q4W, 147 (39.2%) GUS Q8W, and 254 (68.3%) PBO pts, and were included in this analysis. A consistently greater proportion of GUS- than PBO-treated pts achieved W24 categorical outcomes, including those relating to skin, tender joints, and dactylitis, with similar findings for GUS Q4W and Q8W (Figure 1). For continuous endpoints, the benefit of GUS was seen as early as W2 for SJC (W4 for Q8W), TJC, dactylitis (W4 for Q8W), and enthesitis (W4 for Q8W); W8 for FACIT-fatigue, SF-36 PCS, and SF-36 MCS (W16 for Q8W); and W16 for PASI; most endpoints continued to improve through W24 (Figure 2). Across both GUS treatment groups, 43.5%-48.9% of W24 ACR20 non-responders achieved an ACR20 response by W52.

Conclusion: In this cohort of W24 ACR20 non-responders, GUS-treated pts experienced greater benefits than pts receiving PBO in improving both joint disease and other important PsA domains outside the ACR response criteria, which translated to significant improvements in health-related quality of life. These benefits occurred as early as W2 of GUS treatment and showed continued improvement over 24 W, such that considerable proportions of W24 ACR non-responders achieved an ACR20 response by W52. Such improvements in key PsA domains over time among the minority of GUS W24 non-responders is consistent with the known immunomodulatory mechanism of GUS.

Supporting image 1

Supporting image 2


Disclosures: D. McGonagle, AbbVie, Celgene, Eli Lilly, Janssen, Novartis, UCB, Bristol-Myers Squibb(BMS), Amgen, Gilead, Pfizer; D. Haaland, AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb(BMS), Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda, Merck/MSD, UCB, Celgene, Adiga Life-Sciences, Can-Fite Biopharma, Regeneron, Gilead; P. Helliwell, Eli Lilly, AbbVie, Amgen, Janssen, Novartis; A. Marrache, Janssen Pharmaceutical Companies of Johnson & Johnson, Johnson & Johnson; M. Shawi, Janssen Pharmaceutical Companies of Johnson and Johnson; E. Rampakakis, Janssen, JSS Medical Research; P. Nash, AbbVie, Eli Lilly, Janssen, Gilead, Bristol-Myers Squibb (BMS), Celgene; F. Irazoque Palazuelos, AbbVie, Roche, Pfizer, Janssen; A. Kavanaugh, AbbVie, Amgen, Pfizer, Bristol-Myers Squibb(BMS), Centocor-Janssen, UCB, AstraZeneca, Roche.

To cite this abstract in AMA style:

McGonagle D, Haaland D, Helliwell P, Marrache A, Shawi M, Rampakakis E, Nash P, Irazoque Palazuelos F, Kavanaugh A. Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/improvement-in-key-psa-core-domains-with-guselkumab-treatment-in-an-enriched-population-of-acr20-non-responders-at-week-24-post-hoc-analysis-of-two-phase-3-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-in-key-psa-core-domains-with-guselkumab-treatment-in-an-enriched-population-of-acr20-non-responders-at-week-24-post-hoc-analysis-of-two-phase-3-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology